SecBot SecBot
SECBOTREPLAY Home › Report › CRMD

CRMD · CorMedix reported Q1 2026 revenue of $127.4M (21% above $105M…

CorMedix, Inc. · PRESS-RELEASE filed May 14, 2026 at 07:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed May 14, 2026 at 07:30 ET

CorMedix reported Q1 2026 revenue of $127.4M (21% above $105M consensus) and GAAP EPS of $0.43 diluted (30% above $0.33 consensus), driven by strong DefenCath sales ($97.5M) and the acquired Melinta portfolio ($29.9M). The company raised full-year 2026 revenue guidance to $325-345M and adjusted EBITDA guidance to $115-135M, while also announcing positive Phase III ReSPECT trial results for REZZAYO prophylaxis, supporting a bullish outlook.

  • Q1 2026 net revenue $127.4M vs consensus $105.0M (beat by 21.3%)
  • GAAP diluted EPS $0.43 vs consensus $0.33 (beat by 30.3%)
  • DefenCath sales $97.5M, including $9.0M favorable change in estimate
  • Melinta portfolio contributed $29.9M in revenue

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access